Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

r-related death in men and women in the U.S., with 160,000 deaths estimated in 2007. Approximately 80 to 85 percent of these patients will be diagnosed with NSCLC, with the majority being diagnosed with locally advanced or metastatic disease.

About ERBITUX(R) (Cetuximab)

ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. While the mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall therapeutic effect of ERBITUX. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.

ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX as a single agent is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.

ERBITUX is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma (mCRC) in combination with irinotecan for patients who are refractory to irinotecan-based chemotherapy, and as a single agent for patients who are intolerant to irinotecan-based therapy. The effectiveness of ERBITUX for the treatment of EGFR-expressing mCRC cancer is based on obj
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/31/2015)... NEW YORK , July 31, 2015  Seeger Weiss ... Drug Administration (FDA) issued a warning letter to C.R. Bard, ... for not taking adequate strides to correct violations the agency ... aware of these violations after the FDA cited them during ... 05, 2015, in Bard,s Tempe, AZ , ...
(Date:7/31/2015)... 2015 Today, the National Association of ... issued a report urging greater accountability by the ... against websites illegally selling medications online. As detailed ... Program Progress Report for State and Federal Regulators: ... websites illegally distribute medications and avoid retribution. Such ...
(Date:7/31/2015)... , July 31, 2015 The ... press release on July 28, 2015, "Surviving Your ... Launches Fundraising for Patient Safety." A ... sentence should read: "PPAHS is a ... Patients on Opioids. For more information on the National ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3
... 3, 2012  Omeros Corporation (NASDAQ: OMER ) ... interact with each of four additional orphan G protein-coupled ... GPCRs, developing drugs targeting those receptors is extremely difficult. ... 45 percent of the Class A orphan GPCRs. There ...
... 2012 /PRNewswire-Asia/ -- Johnson & Johnson (China) ... Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a ... design, development and commercialization of a porcine ... surgery. The acquisition was completed after obtaining ...
Cached Medicine Technology:Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio 2Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio 3Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio 4Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd. 2
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down ... is currently going on in Chicago at Grant Park. The festival will end ... of North America to Chicago for the annual Lollapalooza. This unique and unbelievably ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to ... it comes time to cook the next meal, making July the most appropriate to ... best grilling tips and recipes. , Make the next cookout different than the ones ...
(Date:7/31/2015)... ... 31, 2015 , ... Coco Libre announced today that their flagship Organic Coconut ... 2015 Vans US Open of Surfing, July 25 through August 2 in Huntington Beach, ... on the market, is a natural choice given the Open’s commitment to sustainable practices. ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... With More than 1,000 Reported Incidents, Caregivers Call ... SAN FRANCISCO, Aug. 31 Home care workers ... organization seeking to decertify the workers, union, saying they had been ... The home caregivers, members of the Service Employees International Union, ...
... ... claim, but has now reversed decision and will cover patient,s life flight , ... Scottsdale, AZ (PRWEB) August 31, 2009 -- ... life flight transportation to be evaluated for a liver transplant. Her doctors told ...
... , SAN FRANCISCO, Aug. 31 /PRNewswire/ ... agency staffed with seasoned marketing professionals and a division of Omnicom,s ... to the position of Director of Strategy for their growing healthcare ... to ECI CEO and President Bara Oscodar. , , ...
... , , LAKE FOREST, ... the world leader in generic injectable pharmaceuticals, today announced that the ... for six new presentations of therapeutic heparin in single- and multiple-dose ... clot formation in central venous catheters and for anticoagulant (blood thinning) ...
... , SCOTTSDALE, Ariz., Aug. 31 Last year, ... of life flight transportation to be evaluated for ... evaluation in order to get on the transplant list. Travel by ground ... Her health insurance company told her they would not cover the ...
... , , , , ... San Diego-based MultiGEN Diagnostics Inc. has launched a novel multi-target DNA ... testing in molecular diagnostics. , , "Until now, ... diagnostic market, forcing laboratories to adopt number of alternative methods such ...
Cached Medicine News:Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 2Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 3Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3Health News:ECI Hires Robin Raff as Director of Strategy 2Health News:Hospira Receives FDA Approval for Six New Presentations of Heparin 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3Health News:Cost Effective Solution for Patient Testing: Introducing Comprehensive and Affordable Molecular Diagnosis With Verifiable Accuracy 2
... Tracking System enables healthcare facilities to provide ... to increase throughput utilizing one low cost ... system utilizes Mobile Aspects active RFID tags, ... wrist band, and can house pertinent patient ...
MONOJECT SUPRA/HONE Blood Collection Needles - Thin Wall...
VACUETTE PaediatricMulti-Sample Needle...
... Needles are preominantly used for routine blood ... colour of the needle protective cap simplifies ... For example, yellow symbolises the needle dimension ... (0.80 mm) and black 22 G (0.70 ...
Medicine Products: